Key Takeaways
- Resilient volumes despite price headwinds: Organic chemicals grew 22% in Q4 as the company added customers and improved costs, offsetting a sharp decline in bromine and lithium raw material prices that crushed inorganic segment revenue.
- Battery materials shift from promise to production: The first lithium electrolyte salts were shipped to customers, trial production began on the electrolyte plant, and management guided to ₹200–250 crore in battery materials revenue for FY25.
- The balance sheet is absorbing growth pains: Working capital swelled as the company compensated for weak export demand by pivoting to the domestic market with longer payment cycles, while employee costs rose from the BuLi Chem and Neogen Ionics build-outs.
- CAPEX is large but levers exist to slow it: The ~₹1,500 crore outlay is mostly funded, but management can moderate the pace by delaying equipment or the electrolyte module if customer approvals or domestic cell manufacturing demand slip.
- What to watch next quarter: The pace of customer approvals for electrolyte salts and electrolytes, the trajectory of lithium and bromine prices, and any sign of a sustained recovery in agrochemical demand.
Battery Materials: The Inflection Quarter
- First commercial shipments achieved: The 200 metric ton per annum lithium salts plant is commissioned, first approved material has been shipped to customers, and trial production has commenced on the remaining 200 metric ton capacity.
- Electrolyte plant ready for trials: Mechanical work on the 2,000 metric ton electrolyte plant is complete and trial production has started.
- Capacity expansion underway: Construction has begun to expand lithium salts capacity to 2,500 metric tons by the end of the current financial year.
- Greenfield facility on track: The larger battery materials plant using MUIS technology is designed, purchase orders for construction are issued, and inauguration is targeted for the second half of FY2026.
- Separator partnership adds a performance layer: An exclusive distribution agreement with a small NASDAQ-listed company covers a separator technology that, combined with a specific electrolyte, can improve battery performance at high temperatures, with potential for joint manufacturing if customer trials succeed.
- Revenue visibility is building but not yet firm: Capacity can produce roughly ₹250 crore, and the company is ready to do ₹200–250 crore in FY25. Electrolyte demand is expected to pick up toward the end of Q2 or early Q3, when customers begin trial cell production. Full utilization, yielding a minimum ₹250–300 crore, is expected in FY26.
- Margins are ROCE-driven, not commodity: At stable lithium prices, battery materials should deliver around 16% EBITDA margins. Better margins are possible only if the company provides something that improves customer cell performance, earning the right to a higher take.
Harin Kanani: "it is a little bit too early for me to say exactly how much it will be"
The BuLi Chem Acquisition: A Unique Chemistry Platform
- Three strategic layers unlocked: The acquisition supports Advanced Intermediates and CSM through a unique combination of organolithium compounds with bromine derivatives, with the lithium by-product recycled back into the process. It also gives Neogen entry into a global oligopoly: only two or three lithium mining companies globally produce organolithium.
- Customer visibility is expanding: With a proven 17-year plant now under Neogen’s ownership, the company is gaining access to pharma, specialty material, and even semiconductor customers, increasing its visibility to a larger group of international companies.
- Amalgamation filing imminent: Based on the Board’s recommendation, the company will file for amalgamation of BuLi Chemicals with Neogen, as most customers have already registered the ownership transfer. Additional synergies include common exposure to pharma and agrochemical customers, internal use of organolithium, by-product recycling, and lower administrative costs.
- The innovation pitch is resonating: The ability to combine bromine and organolithium chemistry is unique globally, and customers respond positively, especially given lithium price volatility.
Harin Kanani: "So that is a combination which is very unique in the world and whenever we want to innovate for our customers, they simply love this idea, especially when they know lithium price is going to fluctuate."
Legacy Business: Divergence and Recovery Signals
- Organic chemicals delivered strong volume growth: The segment grew 22% in Q4 and 17% for FY24, driven by higher volumes across product categories, even as raw material prices fell sharply.
- Inorganic chemicals were crushed by raw material prices: Revenue declined 53% in Q4 due to the significant drop in bromine and lithium prices, masking underlying volume resilience.
- Specialty pharma is normalizing and growing: Beyond bulk pharma products like statins and sartans, specialty pharma is doing well. A long-term agreement with one innovator customer for supplying intermediates to their APIs is growing very fast, compensating for lost demand from traditional bulk pharma customers.
- Agro remains the weak spot: The agrochemical segment has still not seen recovery. Some increase in bulk pharma was visible in April, with sartans revenue starting to increase, but it is too early to determine whether this is inventory build-up or a sustained recovery.
- CSM pipeline is building for the medium term: Early-stage contract manufacturing has been initiated with 4–5 companies in the agrochem space, and two or three new projects have started, including one combining bromine and N-Butyl lithium. These will contribute meaningfully beyond FY26; the existing pipeline is sufficient until then.
Working Capital and Profitability: The Investment Phase
- Inventory built on a demand bet that did not materialize: Inventory increased because the company planned for full utilization of its organic production facility but saw a dramatic change in agrochemical demand.
- Export weakness forced a domestic pivot with longer cycles: Debtors increased because exports, normally 40–50% of revenue, were impacted by weak agro and pharma export demand. The company compensated through more business in the generic domestic market, where payment terms are longer and realizations take more time.
- Employee costs reflect the new scale: Higher employee costs are primarily attributed to the acquisition of BuLi Chemicals and the setup of Neogen Ionics.
- PAT was weighed down by the CAPEX cycle: Lower profit after tax for FY24 was driven by high depreciation and interest expenses linked to ongoing capital expenditure.
- Working capital improvement is tied to utilization: Over the next two years, as full utilization levels are achieved and new products get approval, there will be significant improvement in working capital days. Current inventory and debtors can support ₹1,000 crore of revenue, and the company aims to achieve that by the end of at least the next financial year.
Raw Material Prices: Stabilization with Upside Risk
- Bromine has likely bottomed: Bromine prices have reached their floor and have started increasing slightly or at least stabilizing, with no further decrease seen in the last year.
- Lithium is off the bottom but still below sustainable levels: Lithium prices touched their lowest point and have just started increasing again, but remain below the long-term sustainable price. Management expects an increase over the next two years, and depending on the pace of demand growth, prices could spike again in FY26 or FY27.
- Price recovery would be a double-edged sword: Higher lithium prices would improve inorganic segment realizations but could also pressure battery materials margins if not passed through, and management declined to disclose current lithium prices when asked.
CAPEX and the Optionality to Slow Down
- The ~₹1,500 crore outlay is mostly funded: The majority of funds are tied up through existing bankers via the project finance route, with 10–12 year term loans including a two-year moratorium on interest and a further one-year moratorium on principal. The Board also approved a ₹500 crore infusion through CCDs.
- Management has built in a brake pedal: The company will watch both international electrolyte salt approvals and domestic electrolyte demand. If required, it can slow down and moderate CAPEX by delaying equipment deliveries or the investment in the electrolyte module.
- A Plan B exists for exports: If the U.S. market turns adverse, the company can go slow on the 3,000 metric ton electrolyte salt facility at the Pakhajan site and build gradually while focusing on the India electrolyte market, where it has maximum rights to win as a first mover with MUIS technology and existing relationships.
- Government policy provides a backstop: Two layers of protection exist: PLI scheme companies must meet value addition criteria for subsidies covering 25–30% of cell production cost, incentivizing local procurement; and government policymakers have promised to increase custom duties to support local industry once domestic component manufacturing is demonstrated.
Harin Kanani: "We will keep watching both, how the international electrolyte salt approvals are progressing as well as how India electrolyte demand is developing. In India, mostly, we feel it is a demand issue depending on how well the Indian battery industry starts manufacturing cells. And if required we can slowdown and we can moderate our CAPEX accordingly."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Battery materials plant inauguration | Greenfield facility using MUIS technology | Second half of FY2026 |
| Lithium salts capacity expansion | Expand to 2,500 metric tons per annum | End of current financial year |
| Battery materials revenue FY25 | ₹200–250 crore; electrolyte demand picks up when customer cell trials begin | End of Q2 / early Q3 FY25 |
| Battery materials revenue FY26 | Minimum ₹250–300 crore at full utilization, plus contribution from additional capacity coming online | FY26 |
| Legacy revenue scale | ₹1,000 crore-plus revenue from Neogen Chemicals, supported by current working capital base | FY26 |
| Electrolyte salt customer approvals | Trial volumes shipping now; permissions expected | End of Q2 FY25 |
| Electrolyte plant full utilization | Depends on how fast initial customers stabilize at even 1 GWh capacity | Q4 FY25 or Q1 FY26 |
| CAPEX moderation trigger | Slow down or delay equipment/electrolyte module if approvals or domestic demand slip | Ongoing, watch through Q2/Q3 FY25 |
| Working capital improvement | Significant reduction in days as utilization rises and new products are approved | Over the next 2 years |
Key Metrics
| Metric | Q4 FY24 |
|---|---|
| Consolidated revenue | ₹200 cr |
| Organic revenue growth | 22% |
| Inorganic revenue decline | 53% |
| Organic chemicals revenue | ₹169 cr |
| Inorganic chemicals revenue | ₹31 cr |
| EBITDA | ₹36 cr, +10% YoY |
| EBITDA margin | 18% |
| PAT | ₹17 cr, +18% YoY |
| FY24 consolidated revenue | ₹691 cr |
| FY24 EBITDA | ₹110 cr |
| FY24 EBITDA margin | 16% |
| FY24 PAT | ₹36 cr |
| FY24 organic chemicals revenue | ₹543 cr, +17% YoY |
| FY24 inorganic chemicals revenue | ₹148 cr |
| FY24 domestic/export mix | 73% / 27% |
| Consolidated net debt (FY24) | ₹381 cr, including current maturities of long-term debt |
| Final dividend recommended (FY24) | ₹2 per share, 20% of face value |
| Organic chemicals capacity utilization | 60%–65% |
| Inorganic chemicals capacity utilization | 75%–80%, close to full utilization |
| Organolithium revenue contribution | ₹17–18 cr |
| Volume growth, inorganic chemicals (Q4) | 4%–5% YoY |
| Volume growth, organic chemicals (FY24) | 25%–30% |
| Battery materials revenue readiness (FY25) | ₹200–250 cr |
| Battery materials minimum revenue target (FY26) | ₹250–300 cr |
| Total upcoming CAPEX (all sites) | ~₹1,500 cr |
| CAPEX expected in FY25 | ₹400–500 cr, balance in FY26 |
| Debt portion of ₹1,500 cr CAPEX | ~₹1,150 cr, funded by bankers |
| Lithium salts capacity commissioned | 200 MTPA of 400 MTPA plant, first approved material shipped |
| Lithium salts capacity expansion target | 2,500 MTPA by end of FY25 |
| Electrolyte plant capacity | 2,000 MT, mechanical work complete, trial production commenced |
| India electrolyte demand estimate | 160 GWh, ~120 GWh EV, 30–40 GWh energy storage |
| Electrolyte salt as percentage of cell cost | 4%–5% |
| Electrolyte as percentage of cell cost | 8%–10% |
| Revenue breakup target by FY26 (non-battery) | 40% Bromine Derivatives, 20% CSM, 20% Advanced Intermediates, 15–20% non-battery lithium compounds |
| Current revenue breakup (non-battery) | 50–55% Bromine Derivatives, 30% Advanced Intermediates, 15–20% lithium chemicals |
| CCD infusion approved | ₹500 cr |
| Term loan tenure for Pakhajan site | 12 years, 2-year interest moratorium, 1-year principal moratorium, 9-year repayment |
| Government PLI subsidy as percentage of cell production cost | 25%–30% |
| U.S. import duty on electrolyte and components from China | 25% |